Corvus Pharmaceuticals Inc (CRVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $897.52M
Last updated: Nov 17, 2026 at 4:43 PM ET
Corvus Pharmaceuticals Inc (CRVS) Statistics
Corvus Pharmaceuticals (CRVS) has a market cap of $897.52M and an enterprise value of $882.50M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 11.65% from a year earlier.
Total Valuation
Enterprise value is 1.67% below the market cap, as cash exceeds debt.
| Market Cap | $897.52M |
|---|---|
| Enterprise Value | $882.50M |
| Latest price (Nov 17, 2026) | $10.17 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 15.96% over 52 weeks and trades 7.80% below its 50-day average.
| Beta (1Y) | 0.67 |
|---|---|
| 52-Week Change | +15.96% |
| 1-Month Change | +5.39% |
| 3-Month Change | -33.96% |
| 6-Month Change | -11.57% |
| 5-Year Change | +121.41% |
| 10-Year Change | -24.87% |
| Total Return (1Y) | +15.96% |
| Total Return (3Y CAGR) | +91.39% |
| Total Return (5Y CAGR) | +24.37% |
| Return vs SPY (1Y) | +0.32% |
| Max Drawdown (1Y) | -63.24% |
| Max Drawdown (3Y) | -70.50% |
| Sharpe Ratio (1Y) | 0.10 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $11.03 |
| 200-Day Average | $13.89 |
| 52-Week Range | $6.39 to $26.95 |
| RSI (14 Days) | 44.5 |
| Average Volume (20 Days) | 986.39K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 13.38x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 13.38x |
|---|---|
| Quick Ratio | 13.38x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -30.87% over the last 12 months, against a 5-year average of -80.85%.
| Return on Equity (ROE) | -30.87% |
|---|---|
| Return on Assets (ROA) | -28.73% |
| ROE (5Y Average) | -80.85% |
| ROA (5Y Average) | -54.25% |
| ROIC (5Y Average) | -20.43% |
Scores
CRVS has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$26.00K |
| Operating Income | -$67.75M |
| Pretax Income | -$61.41M |
| Net Income | -$64.31M |
| Reported EPS (TTM) | -$0.71 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.05% of the $223.88M in total assets.
| Cash and Equivalents | $15.01M |
|---|---|
| Total Debt | $0 |
| Net Cash | $15.01M |
| Net Cash Per Share | $0.16 |
| Working Capital | $190.93M |
| Shareholder Equity | $208.32M |
| Book Value Per Share | $2.25 |
| Total Assets | $223.88M |
| Total Liabilities | $15.56M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $764.00K of capital spending, operating cash flow left -$47.94M of free cash flow.
| Operating Cash Flow | -$47.18M |
|---|---|
| Capital Expenditures | $764.00K |
| Free Cash Flow | -$47.94M |
| FCF Per Share | -$0.57 |
| Depreciation and Amortization | $905.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -1.36% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -1.36% |
Dividends and Yields
CRVS does not pay a dividend. Its free cash flow yield is -5.10%.
| FCF Yield | -5.10% |
|---|---|
| Buyback Yield | -20.14% |
| Shareholder Yield | -20.14% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CRVS
What is CRVS's market cap?
Corvus Pharmaceuticals has a market cap of $897.52M. Its enterprise value, which adds debt and subtracts cash, is $882.50M.
How many shares of CRVS are outstanding?
Corvus Pharmaceuticals has 92.49M shares outstanding. The count is up 11.65% from a year earlier.
Does CRVS pay a dividend?
No. Corvus Pharmaceuticals does not pay a dividend.
How much debt does CRVS have?
Corvus Pharmaceuticals has $0 of total debt and $15.01M of cash and equivalents, a net cash position of $15.01M.
CRVS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors